PeerVoice Internal Medicine Video

PeerVoice is committed to producing and distributing evidence-based, independently-created medical education in Internal Medicine that is designed to positively impact patient care. Activities can either be accredited or non-accredited but are always driven by the learning and practice needs of healthcare professionals. Learn more at: https://peervoice.com.

343 episodes

15d ago latest

weekly cadence

English language

▶ Play latestRSS feed Website Science Health Fitness Medicine Education

https://c.peervoice.com/podcast/xml/internal_medicine_video.xml

Episodes 298

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices
2d ago · 38:31
For the complete activity, including supporting material, please visit https://www.peervoice.com/CTG860. Presented by Hannele Yki-Järvinen, MD, FRCP and Jeremy Tomlinson, MD, PhD, FRCP. Learning Objectives: Identify individuals who warrant evaluation for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis based on the presence of cardiometabolic risk factors; Apply available non-invasive scoring systems such as the Fibrosis-4 (FIB-4) Index to predict presence of hepatic fibrosis; Use the outcomes of non-invasive tests to guide referral of individuals to specialist care for su
Richard Lafayette, MD, FACP - A Case-Based Masterclass Series: Guidelines to Practice in the Management of IgAN
2d ago · 28:57
For the complete activity, including supporting material, please visit https://www.peervoice.com/JQF860. Presented by Richard Lafayette, MD, FACP. Learning Objectives: Describe the key updates to guideline-recommended treatment targets in the management of IgA nephropathy (IgAN); Utilize guideline-recommended approaches to evaluate and stratify risk in patients with IgAN; Implement evidence-based treatment strategies to optimize outcomes in patients with IgAN; Propose practical strategies to monitor response to treatment, in the context of guideline-recommended treatment targets for IgAN.
Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement
15d ago · 19:20
For the complete activity, including supporting material, please visit https://www.peervoice.com/RZR860. Presented by Luis Querol, MD, PhD and Jean-Philippe Plançon. Learning Objectives: Describe the multifaceted impact of chronic inflammatory demyelinating polyneuropathy (CIDP); Explain the limitations of established treatment strategies for CIDP that are driving the need for treatment innovations; Recognise the most recently approved and emerging treatment approaches for CIDP.
Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes
15d ago · 32:12
For the complete activity, including supporting material, please visit https://www.peervoice.com/KGV860. Presented by Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP; Amer Durrani, FRCS (Plast); and Philip Albery, LLB. Learning Objectives: Identify the unmet needs in the management of high-risk cutaneous squamous cell carcinoma (CSCC), including the challenges and morbidity associated with existing interventions; Assess patient preferences and quality-of-life considerations when making treatment decisions, including the impact on physical and mental wellbeing; Evaluate data from tri
Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes
22d ago · 1:20:49
For the complete activity, including supporting material, please visit https://www.peervoice.com/PMG860. Presented by Meletios Dimopoulos, MD; Eilidh Duncan, PhD; Monique Minnema, MD, PhD and Fredrik Schjesvold, MD, PhD. Learning Objectives: Recognise unmet needs experienced by patient populations diagnosed with NDMM, including patient- and clinician-level barriers to shared decision-making; Recall clinical trial data evaluating the safety and efficacy of guideline-recommended treatment approaches for the front-line management of NDMM; Formulate individualised treatment plans for the managemen
Jürgen Floege, MD / Richard Lafayette, MD, FACP - Strategies to Success in IgAN Management: Harmonizing the Latest Evidence and Guidance to Maximize the Potential of Foundation Treatment Strategies
1mo ago · 29:43
For the complete activity, including supporting material, please visit https://www.peervoice.com/NCD860. Presented by Jürgen Floege, MD and Richard Lafayette, MD, FACP Learning Objectives: Recognize the role of the gut mucosal immune system in the pathogenesis of IgA nephropathy (IgAN); Summarize the evidence related to current guideline-recommended treatment approaches to address the IgAN-specific drivers of nephron loss; Formulate practical strategies to identify when to escalate care to optimize outcomes in patients with IgAN; Integrate the KDIGO 2025 recommendations into clinical practice
One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings
1mo ago · 26:33
For the complete activity, including supporting material, please visit https://www.peervoice.com/GVP860. Presented by Miguel Bajouco, MD, MSc; David Cassiman, MD, PhD; Rebecca Karp Leaf, MD; Katherine Pocius, MD, MPH; and Paulo Lima Serrano, MD, PhD Learning Objectives: Recognise the importance of early suspicion of acute hepatic porphyria (AHP) in reducing diagnostic delays and improving outcomes; Explain how to test for AHP in patients with indicative clinical symptoms and signs; Analyse presenting symptoms and clinical history to determine when AHP should be strongly suspected and diagnosti
John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community
1mo ago · 17:39
For the complete activity, including supporting material, please visit https://www.peervoice.com/WBP860. Presented by John Friedewald, MD, FASN, FAST Learning Objectives: Identify emerging data that can be applied in current clinical practice to optimize the care and outcomes of kidney transplant recipients; Evaluate investigational immunosuppressants, therapies and technologies, and overall research trends to anticipate potential shifts in future standards of care in kidney transplantation.
Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management
1mo ago · 16:39
For the complete activity, including supporting material, please visit https://www.peervoice.com/VUR860. Presented by Kausik Ray, MD, MPhil (Cantab), FMedSci. Learning Objectives: Discuss the rationale and importance of earlier recognition of patients with and at high risk of atherosclerotic cardiovascular disease (ASCVD); Identify key features associated with high-risk ASCVD; Apply practical strategies for achieving effective lipid control in individuals at high risk of ASCVD.
Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health
2mo ago · 1:17:14
For the complete activity, including supporting material, please visit https://www.peervoice.com/VAC860. Presented by Carel le Roux, MBChB, MSc, PhD; Biykem Bozkurt, MD, PhD; Domenica M. Rubino, MD; and Michael Donnelly-Boylen, MS. Learning Objectives: Describe the pathophysiologic relationship between obesity, metabolic dysfunction, and end-organ injury across cardiovascular, renal, and metabolic disease; Evaluate key clinical and psychosocial factors that influence multidisciplinary management decisions for patients with obesity and related cardiovascular-renal-metabolic disease; Apply evide
Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease
2mo ago · 25:41
For the complete activity, including supporting material, please visit https://www.peervoice.com/YWG860. Presented by Hannele Yki-Järvinen, MD, FRCP and Cyrielle Caussy, MD, PhD. Learning Objectives: Recognise the bidirectional relationship between type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH), including the impact of MASH on glycaemic control, insulin resistance, and complications; Explain the rationale for prompt identification and active management of individuals with MASH and fibrosis, based on the increased risk of adverse liver outcomes associated with
Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative
2mo ago · 21:06
For the complete activity, including supporting material, please visit https://www.peervoice.com/QZY860. Presented by Andrea Necchi, MD and Melanie Costin. . Learning Objectives: Recognise the benefits of implementing shared decision-making when managing patients with more advanced stages of bladder cancer, including muscle-invasive bladder cancer (MIBC) and locally advanced or metastatic urothelial carcinoma (la/mUC); Implement recommended patient communication and empowerment techniques to encourage greater understanding of available treatment options among patients with MIBC or la/mUC.
David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World
2mo ago · 20:43
For the complete activity, including supporting material, please visit https://www.peervoice.com/DMZ860. Presented by David Alain Wohl, MD; and Antonella Castagna, MD. Learning Objectives: Explain the clinical rationale for rapid antiretroviral therapy (ART) in people with HIV; Evaluate evidence on the benefits and limitations of rapid ART in HIV; Formulate practical steps to align rapid ART practices in HIV with both guideline expectations and real-world realities.
Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer
2mo ago · 19:41
For the complete activity, including supporting material, please visit https://www.peervoice.com/CFH860. Presented by Javier Cortés, MD, PhD and Laura Huppert, MD. Learning Objectives: Recall the results of clinical trials evaluating TROP2-directed antibody-drug conjugates (ADCs) as monotherapy or in combination with a PD-1 inhibitor in frontline treatment settings of HR+/HER2- or triple-negative metastatic breast cancer (TNBC); Assess the potential clinical impact of these data, including patient populations included in trials and how these relate to patients seen in the real-world clinic..
Georgios Tsivgoulis, MD, PhD, MSc - Navigating the Latest Evidence Surrounding Current and Emerging Strategies for Secondary Stroke Prevention
3mo ago · 20:17
For the complete activity, including supporting material, please visit https://www.peervoice.com/RYV860. Presented by Georgios Tsivgoulis, MD, PhD, MSc. Learning Objectives: Recognise recently presented evidence evaluating current secondary stroke prevention (SSP) strategies in people with previous non-cardioembolic ischaemic stroke (NCIS) or high-risk transient ischaemic attack (TIA); Recall recent data evaluating investigational oral anticoagulants (eg, Factor XIa inhibitors) for SSP in people with previous NCIS or high-risk TIA.
Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer
3mo ago · 54:23
For the complete activity, including supporting material, please visit https://www.peervoice.com/UGY860. Presented by Trisha Wise-Draper, MD, PhD; Christine H. Chung, MD; Renata Ferrarotto, MD; and Kevin Harrington, PhD, FRCP, FRCR. Learning Objectives: Explain the implications of human papillomavirus (HPV) status in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) for patient outcomes and quality of life; Interpret clinical trial data stratified by HPV status to identify limitations of current standard-of-care therapies for non-HPV–associated recurrent/metastatic HNSCC; Expl
Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice
3mo ago · 35:42
For the complete activity, including supporting material, please visit https://www.peervoice.com/FAK860. Presented by Sven Francque, MD, PhD; and José Luis Calleja Panero, MD, PhD. Learning Objectives: Recall the rationale for prompt identification of metabolic dysfunction-associated steatohepatitis (MASH) in gastroenterology patients, including the high prevalence in specific patient groups, the risk of progression, and the availability of novel treatments; Use recommended non-invasive blood- and image-based methods to evaluate for evidence of steatosis and fibrosis among individuals with car
Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
3mo ago · 1:20:09
For the complete activity, including supporting material, please visit https://www.peervoice.com/ZRT860. Presented by Anjali Tiku Owens, MD; Andrew Willeford, PharmD, PhD, BCCP; and Rachel Lavelle, PharmD, BCCP Learning Objectives: Differentiate between obstructive and non-obstructive hypertrophic cardiomyopathy (oHCM and nHCM) based on their pathophysiology and current guideline-directed management strategies; Evaluate the efficacy and safety of cardiac myosin inhibition as monotherapy or first-line therapy for oHCM in comparison to beta-blockade; Compare available cardiac myosin inhibitors (
Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass
3mo ago · 29:59
For the complete activity, including supporting material, please visit https://www.peervoice.com/QYU860. Presented by Martin Köbel, MD and Diana N. Ionescu, MD, MSc (EMMP). Learning Objectives: Explain the staining pattern of FRα-positive in tubo-ovarian and peritoneal high-grade serous carcinoma; Score the intensity and distribution of FRα expression in histology section of tubo-ovarian and peritoneal high-grade serous carcinoma; Discuss the implications of immunohistochemistry assessment of tubo-ovarian and peritoneal high-grade serous carcinoma for FRα expression on the subsequent course of
Irina Turchin, MD, FRCPC, DABD / Hélène Veillette, MD, FRCPC - On the Case: Practical Insights to Individualize Biologic Treatment in Moderate-to-Severe Hidradenitis Suppurativa
3mo ago · 26:31
For the complete activity, including supporting material, please visit https://www.peervoice.com/ACF860. Presented by Irina Turchin, MD, FRCPC, DABD and Hélène Veillette, MD, FRCPC. Learning Objectives: Review the available biologics for the management of hidradenitis suppurativa (HS); Discuss the clinical profiles of the available biologics in patients with HS; Evaluate the clinical factors that may guide treatment selection among the available biologics in patients with HS.
Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes
4mo ago · 1:19:25
For the complete activity, including supporting material, please visit https://www.peervoice.com/ACQ860. Presented by Colin M. Dayan, MA, MBBS, FRCP, PhD; Michael J. Haller, MD; and Olga Kordonouri, MD. Learning Objectives: Explain the clinical rationale and existing evidence for use of immunomodulatory therapies to delay the progression of type 1 diabetes (T1D); Identify practical workflows and protocols that facilitate the potential integration of immunomodulatory infusions into endocrinology practice, including care pathways for T1D; Evaluate patient perspectives and considerations related
Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can
4mo ago · 20:02
For the complete activity, including supporting material, please visit https://www.peervoice.com/PXK860. Presented by Javier Ampuero, MD, PhD and Meena B. Bansal, MD, FAASLD. Learning Objectives: Explain the rationale for prompt identification and active management of individuals with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, based on the increased risk of adverse liver outcomes associated with progression of fibrosis; Evaluate the impact of novel MASH-targeted therapies, such as THR-β agonists, on the underlying pathophysiology and progression of the disease; Ident
Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy
4mo ago · 30:04
For the complete activity, including supporting material, please visit https://www.peervoice.com/TZX860. Presented by Jonathan Barratt, PhD, FRC. Learning Objectives: Describe the relationship between the multi-hit hypothesis and disease trajectory in patients with IgA nephropathy (IgAN); Summarise the role and therapeutic implications of complement pathway dysregulation in IgAN disease progression; Differentiate between emerging therapeutic targets under investigation in patients with IgAN; Interpret data from clinical trials examining emerging therapies, including complement inhibitors, in t
Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade
5mo ago · 29:29
For the complete activity, including supporting material, please visit https://www.peervoice.com/FAN860. Presented by Austin Kulasekararaj, MD, MRCP, FRCPath; and Bruno Fattizzo, MD Learning Objectives: Discuss the criticality of achieving and sustaining terminal complement inhibition in patients with paroxysmal nocturnal haemoglobinuria (PNH), and the evidence for C5 inhibitor therapy on key efficacy outcomes; Recognise that extravascular haemolysis (EVH) is a potential limitation of terminal complement inhibition with C5 inhibitors and the need to target proximal complement blockade in patie
Ashkan Shoamanesh, MD, FRCPC - Turning Pathophysiologic Promise Into Evidence-Based Potential: Are Factor XIa Inhibitors Ready for Prime Time in Secondary Stroke Prevention?
5mo ago · 1:10:40
For the complete activity, including supporting material, please visit https://www.peervoice.com/CMY860. Presented by Ashkan Shoamanesh, MD, FRCPC; Valeria Caso, MD, PhD; Seemant Chaturvedi, MD; and Jeffrey L. Saver, MD, FAHA, FAAN, FANA. Learning Objectives: Explain the rationale and potential role for use of Factor XIa (FXIa) inhibition in the prevention of ischemic stroke following an acute non-cardioembolic ischemic stroke (NCIS) or high-risk transient ischemic attack (TIA); Evaluate the design and methodology of enrolled populations for key phase 3 trials of FXIa inhibitors for secondary

Episodes

Reading the feed…

Also on peervoice.com

More Science shows

Arizona Science

azpm.org

510 episodes · 9d ago

WiTcast

witcastthailand.com

357 episodes · 8d ago

Evrim Ağacı ile Bilime Dair Her Şey!

evrimagaci.org

557 episodes · 8d ago

A Moment of Science

prxu.org

1,000 episodes · 9d ago

Groks Science Radio Show and Podcast

ocf.berkeley.edu

1,000 episodes · 11d ago

Ask the Naked Scientists

thenakedscientists.com

802 episodes · 9d ago

PeerVoice Internal Medicine Video

Episodes 298

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices

Richard Lafayette, MD, FACP - A Case-Based Masterclass Series: Guidelines to Practice in the Management of IgAN

Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes

Jürgen Floege, MD / Richard Lafayette, MD, FACP - Strategies to Success in IgAN Management: Harmonizing the Latest Evidence and Guidance to Maximize the Potential of Foundation Treatment Strategies

One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Georgios Tsivgoulis, MD, PhD, MSc - Navigating the Latest Evidence Surrounding Current and Emerging Strategies for Secondary Stroke Prevention

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass

Irina Turchin, MD, FRCPC, DABD / Hélène Veillette, MD, FRCPC - On the Case: Practical Insights to Individualize Biologic Treatment in Moderate-to-Severe Hidradenitis Suppurativa

Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes

Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Ashkan Shoamanesh, MD, FRCPC - Turning Pathophysiologic Promise Into Evidence-Based Potential: Are Factor XIa Inhibitors Ready for Prime Time in Secondary Stroke Prevention?

Episodes

Also on peervoice.com

PeerVoice Internal Medicine Audio

PeerVoice Clinical Pharmacology Video

PeerVoice Oncology & Haematology Video

PeerVoice Clinical Pharmacology Audio

PeerVoice Oncology & Haematology Audio

PeerVoice Endocrinology & Metabolic Disorders Video

More Science shows

Arizona Science

WiTcast

Evrim Ağacı ile Bilime Dair Her Şey!

A Moment of Science

Groks Science Radio Show and Podcast

Ask the Naked Scientists

Episodes 298

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices

Richard Lafayette, MD, FACP - A Case-Based Masterclass Series: Guidelines to Practice in the Management of IgAN

Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes

Jürgen Floege, MD / Richard Lafayette, MD, FACP - Strategies to Success in IgAN Management: Harmonizing the Latest Evidence and Guidance to Maximize the Potential of Foundation Treatment Strategies

One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Georgios Tsivgoulis, MD, PhD, MSc - Navigating the Latest Evidence Surrounding Current and Emerging Strategies for Secondary Stroke Prevention

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass

Irina Turchin, MD, FRCPC, DABD / Hélène Veillette, MD, FRCPC - On the Case: Practical Insights to Individualize Biologic Treatment in Moderate-to-Severe Hidradenitis Suppurativa

Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes

Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Ashkan Shoamanesh, MD, FRCPC - Turning Pathophysiologic Promise Into Evidence-Based Potential: Are Factor XIa Inhibitors Ready for Prime Time in Secondary Stroke Prevention?